Figure 7 | Scientific Reports

Figure 7

From: ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC

Figure 7

A proposed graphical summary of new personalized therapy treatments. (a) Osimertinib tumors responded to the efficient TKI but a selection of drug resistant sub-population appears. (b) Osimertinib resistant tumors showed more aggressive phenotype and different personalized therapeutic approach will be necessary based on the mutational status of p53. The graphical summary was produced by the authors using free BioRender platform.

Back to article page